Opinion|Videos|March 11, 2025

Quality of Life and Patient Outcomes in mCRC Treatment

Experts discuss practical strategies used by their institutions to manage treatment-related toxicities with third-line therapies for metastatic colorectal cancer (mCRC) and share their experiences on how third-line therapy options have impacted patients’ quality of life.

Video content above is prompted by the following:

  • What practical strategies does your institution use to manage treatment-related toxicities with third-line therapies for mCRC?
  • In your experience, how have the third-line therapy options impacted your patients’ quality of life?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo